MedTrace Logo

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

NCT00240019 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-10-17

No results posted yet for this study

Summary

The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Addition of furosemide 20 mg oral bid to baseline regimen

Sponsors & Collaborators

Principal Investigators

  • Timothy W Meyer, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Completion
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240019 on ClinicalTrials.gov